Thalia Therapeutics Plc

Thalia Therapeutics Plc is a biotechnology company based in London, United Kingdom, that develops and delivers RNA-based therapeutics and technologies for oncology and cardiovascular disease. It develops nanoparticle silica delivery systems intended to enhance the cellular delivery and potency of cancer treatments and vaccines. Its pipeline includes Nuvec, an RNA therapeutics pipeline, and Liptide, a platform designed to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company is also developing N4 101, an orally delivered inflammation inhibitor for inflammatory bowel disease, and ECP105 for the prevention of ocular scarring. It collaborates with the Centre for Continuous Manufacturing and Advanced Crystallisation at the University of Strathclyde on the scale-up and characterisation of Nuvec. Formerly known as N4 Pharma Plc, it changed its name to Thalia Therapeutics Plc in March 2026, was incorporated in 1979, and is based in London, the United Kingdom.